An already approved cancer drug, Yervoy (ipilimumab), improved lung repair ability in a study of mice with idiopathic ...

Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the United ...

Swiss generics and biosimilars major Sandoz (SIX: SDZ) has signed a global collaboration with Shanghai Henlius Biotech (HKEX: ...

MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1]Henlius to ...

A Dutch study finds that rechallenging advanced melanoma patients with ipilimumab and nivolumab (IPINIVO) can lead to ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

Shanghai Henlius Biotech, Inc. (2696.HK) announced a licensing agreement with Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, granting exclusive ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

New treatment approach shows potential in reversing lung damage caused by idiopathic pulmonary fibrosis using immune-based ...

Under the terms of the agreement, Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the US. The core sequence patent for ipilimumab ...